NEW YORK (GenomeWeb) – UgenTec announced today a partnership to develop artificially intelligent software to support interpretation of molecular test results for MDxHealth's ConfirmMDx and SelectMDx for prostate cancer tests.
MDxHealth's SelectMDx test is a liquid biopsy test that identifies patients with an increased risk for clinically significant prostate cancer. The firm's ConfirmMDx is a tissue biopsy test that allows patients to forgo unnecessary repeat biopsy procedures.
"[This automation step] will… also provide our SelectMDx IVD customers with an advanced software they can use [to] support and standardize drafting of result reports," MDxHealth CEO Jan Groen said in a statement.
Financial and other terms of the agreement were not disclosed.
In December, UgenTec expanded a collaboration with Fast Track Diagnostics to include artificially intelligent PCR software on FTR's kits.